SOAT1 and cancer: Aberrant activation of the JAK–STAT signaling pathway has been identified in a wide spectrum of cancers, including melanoma, glioblastoma, and carcinomas of the head and neck, lung, pancreas, bladder, breast, colorectal, and prostate (Gomez et al., 2022; Henrik Heiland et al., 2019; Huang et al., 2020; Habanjar et al., 2023).